Video

Dr. Manish Shah on the METGastric Study

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

The METGastric study examined onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Previous data demonstrated that onartuzumab has activity against the MET receptor. Onartuzumab is considered a novel agent, Shah says, because it is a single chain of the IgG molecule that inhibits the MET pathway and the HGF binding.

Patients were randomized to receive either mFOLFOX6 or mFOLFOX6 combined with onartuzumab. The study ended prematurely due to lack of efficacy, Shah says.

Related Videos
David Samuel Dicapua Siegel, MD
Axel Hauschild, MD, PhD, head, Skin Cancer Trial Center, University Hospital Schleswig-Holstein
 Philip McCarthy, MD
Lova L. Sun, MD, MSCE
Robert M. Rifkin, MD, FACP
Ahmad Tarhini, MD, PhD
Allison Winter, MD
Rocio Garcia-Carbonero, MD
Andrew Ip, MD
Anthony B. El-Khoueiry, MD